# OnCo record nct05941897 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05941897/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05941897", "NCT05941897" ;
  schema:name "A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy"@en ;
  schema:alternateName "LOTOS"@en ;
  schema:description "A phase 2 trial of Ceralasertib and Durvalumab in non-small-cell lung cancer, run by AstraZeneca, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05941897/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05941897> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2023-06-21" ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/ceralasertib/>, <https://onco.cc/drugs/durvalumab/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> .